Clarisyn
The evidence is scattered across papers and databases. The answer shouldn't be.
Clarisyn uses multi-agent analysis to evaluate the literature, compute new results from biomedical data, and bring both into one decision-ready report.
When does Clarisyn actually help?
"What does the evidence actually say?"
"This compound has no published data. What can I still learn about it?"
"Which cell lines are most dependent on this target?"
"Why do these findings disagree?"
"Is this target worth pursuing?"
"Where would this compound fail in development?"
"Does the data support that conclusion?"
"Is this number measured, or predicted?"
Different people. Same moment.
That's when you open Clarisyn.
Ask any biomedical question.
Clarisyn answers it from every angle the question needs, across published literature and experimental data.
Multi-agent analysis in progress.
Automated
Multi-agent analysis across literature and data.
Expert review
A domain expert validates the findings before delivery.
Your decision-ready structured report. In three layers.
Intelligence Report, highlighting the key insights and actionable takeaways.CYP3A4-mediated inhibition at clinical exposure levels presents a low but non-negligible DDI risk. Based on available in vitro and in vivo data, dose adjustment guidance for co-administered substrates is warranted prior to Phase I initiation.Agent consensus: 2 of 3 agents flagged DDI risk as clinically actionable. 1 agent rated risk as low-moderate pending in vivo confirmation.
Reasoning
Reasoning, scoring, and decision steps are shown in full for transparency.
Biological rationale and competitive intensity weighted across 7 criteria.
Each indication scored on a 1–5 scale per criterion, summed into a final weighted score.
Process
Intermediate steps are logged for full process transparency.
All reasoning steps are documented in a single file, with each agent's process clearly separated.
This analysis was built on 49 curated sources, synthesized across 200+ datasets spanning preclinical and clinical literature.
What sets Clarisyn apart?
Every answer draws on academic papers, clinical trial registries, chemical databases and protein structures. No open web, so higher accuracy and lower hallucination risk.
When the answer isn't in a paper yet, Clarisyn runs its own analysis: dependency and viability datasets, expression signatures, structure prediction, docking.
Specialised agents search, analyse and verify, then compare what they found. Agreements, conflicts and gaps are all shown in the report. Nothing is hidden, nothing is filled in.
agent
agent
Reports can be shared, annotated, and discussed with your team. When a second opinion matters more than a second look, an independent expert can review it: professors, MDs, PhD researchers, without leaving the platform.
Can we rerun this with updated tox data?
A layered report, shaped with scientists: the answer, the reasoning, the sources. Why each piece of evidence was trusted, ranked or rejected is always visible.
Is the hepatotoxicity signal observed in rats clinically relevant in humans?